Barr gets tentative OK to sell schizophrenia drug
-
- November
- 9
Barr Pharmaceuticals Inc. announced today that its Pomona-based Barr Laboratories Inc. unit received tentative regulatory approval to begin selling generic Zyprexa Zydis tablets, a drug used to treat schizophrenia.
Barr said it expects to get final Food and Drug Administration approval to sell the drug in April.
The Woodcliff Lake, N.J.-based drug maker will market the tablets in four dosages: 5 milligrams, 10 milligrams, 15 milligrams and 20 milligrams.
Zyprexa, made by Indianapolis-based Eli Lilly & Co., had sales of about $246 million in the 12 months ending September, according to industry data.
This entry was posted
on Thursday, November 9th, 2006 at 5:37 pm by David Schepp.
You can follow any responses to this entry through the RSS 2.0 feed.
Category: New business
Print
| 
Email
My issue is Zyprexa which is only FDA approved for schizophrenia (.5-1% of pop) and some bipolar (2% pop) and then an even smaller percentage of theses two groups.
So how does Zyprexa get to be the 7th largest drug sale in the world?
Eli Lilly is in deep trouble for using their drug reps to ‘encourage’ doctors to write zyprexa for non-FDA approved ‘off label’ uses.
The drug causes increased diabetes risk,and medicare picks up all the expensive fallout.There are now 7 states (and counting) going after Lilly for fraud and restitution.
—Daniel Haszard